

**FOR IMMEDIATE RELEASE**

## **Invitrocue and Angsana Partner with Averywell to Advance Early Lung Cancer Detection Across Asia**

**Singapore**, 15 April 2026 – Invitrocue Limited, together with its clinical diagnostics arm Angsana Molecular & Diagnostics Laboratory Pte Ltd (“Angsana”), today announced a strategic partnership with Averywell Limited to deploy next-generation lung cancer diagnostics across Singapore and broader Asian markets.

This collaboration brings together Averywell’s proprietary miRNA-based liquid biopsy platform (mirLung Dx™) with Invitrocue’s proprietary precision oncology ecosystem and Angsana’s licensed clinical laboratory infrastructure, establishing a powerful, end-to-end solution for early lung cancer detection and risk stratification.

### **Transforming LDCT Lung Nodule Management with Molecular Precision**

Low-dose CT (LDCT) screening has significantly improved early detection of lung nodules. However, a critical clinical challenge remains, accurately distinguishing benign from malignant nodules, often leading to unnecessary invasive procedures, patient anxiety, and increased healthcare burden.

Averywell’s mirLung Dx™ assay directly addresses this gap through a non-invasive blood-based miRNA signature platform, designed to complement LDCT imaging by providing molecular-level diagnostic insight.

### **Core Technology: miRNA Liquid Biopsy for Early Lung Cancer Detection**

At the core of Averywell’s platform is a highly curated panel of circulating microRNAs (miRNAs), which serve as sensitive biomarkers of early tumor biology. These biomarkers are detectable in peripheral blood and reflect early oncogenic transformation.

#### **Key technological features include:**

- Non-invasive blood test enabling repeatable and scalable screening.
- Proprietary bioinformatics algorithms for pattern recognition and risk scoring.
- High sensitivity in early-stage disease, particularly in indeterminate nodules.
- Integration-ready with LDCT workflows, enhancing clinical decision-making.

## Clinical Advantages and Impact

### 1. Improved Diagnostic Accuracy

Enhances the specificity of LDCT by reducing false positives and improving differentiation of benign vs malignant nodules.

### 2. Reduction in Unnecessary Procedures

Minimizes avoidable biopsies, surgeries, and follow-ups, lowering patient risk and healthcare costs.

### 3. Earlier Intervention Window

Detects molecular changes associated with malignancy at earlier stages, enabling more effective treatment planning.

### 4. Scalable Population Screening

A simple blood-based test allows integration into preventive screening programs, corporate health initiatives, and primary care networks.

### 5. Longitudinal Monitoring Capability

Supports repeat testing for nodule surveillance and post-treatment monitoring, enhancing disease management over time.

## Strategic Deployment Across Asia

Under the partnership:

- Averywell will provide technology, scientific support, and continuous innovation.
- Angsana will act as the exclusive laboratory service provider and commercial partner in Singapore.
- Invitrocue will expand adoption across Asia through its personalized oncology platform and partnerships network.

## Leadership Commentaries

Commenting on the transaction, Dr. Cherry Chia, CEO and Founder, Averywell said: “This partnership represents a critical step forward in bridging imaging and molecular diagnostics for lung cancer.” Dr. Fred Chung, Chief Scientific Officer, Invitrocue Group, added and said: “This agreement establishes a strategic collaboration for the clinical deployment and commercialization of Averywell’s mirLung Dx™ test, combining proprietary diagnostics innovation, regulated clinical laboratory execution, and regional market access.”

## About Averywell

Averywell revolutionizes early lung cancer detection and lung nodule management with a groundbreaking miRNA-based liquid biopsy. The company offers non-invasive, precise, and cost-effective technology ensures early detection, enabling timely treatment access for smokers and non-smokers.

## **About Angsana**

Angsana Molecular & Diagnostic Laboratory Pte Ltd (“Angsana”) was established in 2014, and specializes in developing panelised genetic, genomic and molecular-based tests. Angsana’s laboratory developed assays in Allergy and Molecular Allergology, and Molecular Oncology. Angsana is a licensed laboratory by the Ministry of Health Singapore and is also accredited by the College of American Pathologists (CAP) since 2015. With this, Angsana assures clinicians and patients that their tests are robust and meet high standards of clinical quality. Angsana also has strategic tie-ups with several internationally branded healthcare companies to offer a full complement of 21st century healthcare tools to clinical partners in Singapore and beyond. Angsana is a wholly owned subsidiary of Invitrocue.

## **About Invitrocue**

Invitrocue is an innovative life sciences company that specialises in developing ground-breaking 3D cell-based models such as Patient-Derived Organoids (“PDOs”) from all solid cancers. By utilizing Onco-PDO test, Invitrocue perform in vitro drug screenings on PDOs to provide the oncologists with the information to better direct patient therapy and personalized patient treatment. Invitrocue also offers a comprehensive and integrated range of best-in-class early cancer detection Liquid Biopsy clinical test, Personalise Drug sensitivity and dosing tests using patient’s own cancer organoids, best-in-class real time ultra-sensitive treatment Liquid Biopsy clinical tests, and post-treatment relapse monitoring tests.

## **For further information and inquiry, please contact:**

### **AVERYWELL**

*Dr. Cherry Chia*  
CEO, Averywell Limited  
T: +65 84818526  
[cherry.chia@averywell.com](mailto:cherry.chia@averywell.com)  
Website: [www.averywell.com](http://www.averywell.com)

### **ANGSANA MOLECULAR & DIAGNOSTICS LABORATORY**

*Mr. Kevin Lee*  
CEO, Angsana Molecular & Diagnostics Laboratory Pte Ltd  
T: +65 6421 3868  
[kevin.lee@angsanalabs.com](mailto:kevin.lee@angsanalabs.com)  
Website: <https://angsanalabs.com>

### **INVITROCUE**

*Dr. Steven Fang*  
CEO, Invitrocue Ltd  
M: +65 6460 0497  
E: [steven.fang@invitrocue.com](mailto:steven.fang@invitrocue.com)  
Website : <https://invitrocue.com>